These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 18896)

  • 1. Evidence for the existence of regulatory DA receptors in the substantia nigra.
    Di Chiara G; Mereu GP; Vargiu L; Porceddu ML; Mulas A; Trabucchi M; Spano PF
    Adv Biochem Psychopharmacol; 1977; 16():477-81. PubMed ID: 18896
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopamine-stimulated adenylate cyclase in rat substantia nigra: localization and effects of neuroleptics.
    Spano PF; Di Chiara G; Loddo P; Tonon GC; Trabucchi M
    Adv Biochem Psychopharmacol; 1977; 16():613-6. PubMed ID: 18903
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopaminergic receptor activity in substantia nigra in the mechanisms of autoregulation of striatal dopamine release.
    Groppetti A; Parenti M; Cattabeni F; Maggi A; De Angelis L; Monduzzi M; Racagni G
    Adv Biochem Psychopharmacol; 1978; 19():363-71. PubMed ID: 696464
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of effects of tetrahydropalmatine enantiomers on firing activity of dopamine neurons in substantia nigra pars compacta.
    Sun BC; Huang KX; Jin GZ
    Zhongguo Yao Li Xue Bao; 1992 Jul; 13(4):292-7. PubMed ID: 1360741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central dopamine receptors.
    Flückiger E; Vigouret JM
    Postgrad Med J; 1981; 57 Suppl 1():55-61. PubMed ID: 6117849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine receptor mechanisms: behavioral and electrophysiological studies.
    Ungerstedt U; Ljungberg T; Schultz W
    Adv Biochem Psychopharmacol; 1978; 19():311-21. PubMed ID: 29451
    [No Abstract]   [Full Text] [Related]  

  • 8. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topographical distribution and characteristics of dopamine and beta-adrenergic sensitive adenylate cyclases in the rat frontal cerebral cortex, striatum, and substantia nigra.
    Bockaert J; Premont J; Glowinski J; Tassin JP; Thierry AM
    Adv Biochem Psychopharmacol; 1977; 16():29-37. PubMed ID: 196489
    [No Abstract]   [Full Text] [Related]  

  • 10. Neurotensin-dopamine interactions in the substantia nigra of the rat brain.
    Merchant KM; Bush LG; Gibb JW; Hanson GR
    J Pharmacol Exp Ther; 1990 Nov; 255(2):775-80. PubMed ID: 2147039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of castration on dopamine receptor sensitivity in male young rats: behavioral and neurophysiological studies.
    Asakura W; Ohta H; Matsumoto K; Imamura L; Watanabe H; Matsuda H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1994 Apr; 14(2):77-82. PubMed ID: 8042347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No evidence for increased dopamine receptor binding in superresponsive mice after a single dose of neuroleptics.
    Hyttel J
    Adv Biochem Psychopharmacol; 1980; 24():167-73. PubMed ID: 6105773
    [No Abstract]   [Full Text] [Related]  

  • 13. [Dependence of the antipsychotic effect of neuroleptics on their dopamine-blocking properties].
    Arushanian EB
    Farmakol Toksikol; 1982; 45(5):118-26. PubMed ID: 6128251
    [No Abstract]   [Full Text] [Related]  

  • 14. [Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
    Costentin J
    Encephale; 1979; 5(2):121-49. PubMed ID: 38958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurophysiological investigation of effects of the D-1 agonist SKF 38393 on tonic activity of substantia nigra dopamine neurons.
    Carlson JH; Bergstrom DA; Weick BG; Walters JR
    Synapse; 1987; 1(5):411-6. PubMed ID: 2975067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
    Christensen AV; Arnt J; Hyttel J; Svendsen O
    Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
    Meltzer LT; Christoffersen CL; Serpa KA; Razmpour A
    Synapse; 1993 Feb; 13(2):117-22. PubMed ID: 8446920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment.
    Skarsfeldt T
    Synapse; 1992 Jan; 10(1):25-33. PubMed ID: 1346943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.